Skip to main content

Table 1 Characteristics of the studies included in this meta-analysis

From: Cytokine-induced killer cell/dendritic cell combined with cytokine-induced killer cell immunotherapy for treating advanced gastrointestinal cancer

Gender (Male/Female)Mean age (Y)Treatment designFollow-up (M)Study designStagesOutcomes assessed
ExpCon
Jiang/200 6[11]Exp: 21/11;
Con: 18/7
Exp: 54;
Con: 52
CIK + FOLFOX4 (N = 32)FOLFOX4 (N = 25)60ProspectiveGC: IVCR, PR, ORR, QOL
Shi/201 2[12]Exp: 43/31;
Con: 58/19
Exp: 58 ± 2.1;
Con: 56 ± 1.5
CIK + COD (N = 74)COD (N = 77)80RetrospectiveGC: III, IVOS, PFS
Zhao/201 3[13]Exp: 40/13;
Con: 87/25
NACIK + FUP or FOLFOX4 (N = 53)FUP or FOLFOX4 (N = 112)120RetrospectiveGC: II, IIIOS, PFS
Lin/201 5[14]Exp: 76/58;
Con: 64/57
NADC–CIK + 5-FU, FOLFOX/XELOX (N = 134)5-FU, FOLFOX/XELOX (N = 121)50ProspectiveCRC: KPS score > 60Thrombocytopenia, nausea, vomiting, abnormal liver function
Mu/201 6[15]Exp: 10/3;
Con: 10/5
NACIK + FOLFOX4/DCF (N = 13)FOLFOX4/DCF (N = 15)24ProspectiveGC: III, IVOS, PFS, CR, PR, ORR, thrombocytopenia, nausea, vomiting, neutropenia
Zhao/201 6[16]Exp: 41/20;
Con: 41/20
Exp: 58;
Con: 60
CIK + FOLFOX4 (N = 61)FOLFOX4 (N = 61)72ProspectiveCRC: KPS score > 70OS, PFS, CR, PR, ORR, neutropenia
Peng/201 7[17]Exp: 14/9;
Con: 15/8
Exp: 52.2 ± 7.9;
Con: 51.4 ± 8.5
CIK + FOLFOX4(N = 23)FOLFOX4 (N = 23)50ProspectiveCRC: II, IIIQOL, nausea, vomiting, abnormal liver function, myelosuppression
Wang/201 7[18]Exp: 38/13;
Con: 73/23
NACIK + FP (N = 51)FP (N = 96)80ProspectiveGC: II, IIIOS, PFS, myelosuppression
Xie/201 7[19]Exp: 39/32;
Con: 40/31
Exp: 55.3 ± 14.6;
Con: 55.6 ± 14.3
DC-CIK + FOLFIRI (N = 71)FOLFIRI (N = 71)120RetrospectiveCRC: III, IVOS, PFS, QOL
  1. CIK Cytokine-induced killer biotherapy, COD cisplatin, oxaliplatin, and docetaxel, Con control group, CR complete response, DC dendritic cell, DCF docetaxel, cisplatin, 5-florouracil, Exp experimental group, FOLFIRI irinotecan (CPT-11), leucovorin (LV), and 5-FU regimen, FOLFOX4 5-fluorouridine, leucovorin, and oxaliplatin, FP 5-fluorouracil- and platinum, KPS Karnofsky performance status, M months, NA Not available, ORR overall response rate, OS overall survival, PFS progression-free survival, PR partial response, QOL quality of life, Y years